Correlation of Glasgow Prognostic Score or Procalcitonin to Clinical Variables in Patients with Pretreatment Lung Cancer

作者: Young Kim , Ji-Yoon Seok , Kyung-Yae Hyun , Gil-Hyun Lee , Seok-Cheol Choi

DOI: 10.15616/BSL.2016.22.1.9

关键词:

摘要: Unfortunately, the five-year survival rate of lung cancer is relatively low compared with other cancers. Therefore, better predictors are need for prognosis, therapeutic strategy, risk stratification and predicting long-term mortality cancer. Recently, increasing data suggest that Glasgow Prognostic Score (GPS) procalcitonin levels useful predictor prognosis. In this study, we retrospectively investigated correlation GPS or to clinical variables in patients pretreatment 135 cancer, GPS, procalcitonin, demographic characteristics, hematological, coagulation, biochemical, inflammatory cardiac markers were measured. Monocyte, eosinophil, basophil, neutrophil lymphocyte ratio, red cell distribution width (RDW), platelet mean volume platecrit D-dimer prothrombin time (PT) higher, whereas was lower than their normal ranges. Glucose sodium low, gamma glutamyl transferase (GGT), total bilirubin, creatinine inorganic phosphorus concentrations increase Procalcitonin, high sensitivity C-reactive protein troponin-I elevated had significantly positive negative relations stage, troponin-I. Based on data, may be a potent

参考文章(42)
P Maruna, K Nedelníková, R Gürlich, Physiology and genetics of procalcitonin. Physiological Research. ,(2000)
Sławomir Mikosiński, Agnieszka Celnik, Krzysztof Kaczka, Wojciech Fendler, Lech Pomorski, Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. ,vol. 21, pp. 169- 178 ,(2012)
M. Detmar, A. M. Dvorak, L. F. Brown, H. F. Dvorak, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology. ,vol. 146, pp. 1029- 1039 ,(1995)
H. H. Liu, J. B. Guo, Y. Geng, L. Su, Procalcitonin: present and future. Irish Journal of Medical Science. ,vol. 184, pp. 597- 605 ,(2015) , 10.1007/S11845-015-1327-0
Rodney E. Shackelford, Moiz Vora, Kim Mayhall, James Cotelingam, ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes & Cancer. ,vol. 5, pp. 1- 14 ,(2014) , 10.18632/GENESANDCANCER.3
Masahiro Nakayama, Keiji Tabuchi, Akira Hara, Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer. Head and Neck-journal for The Sciences and Specialties of The Head and Neck. ,vol. 37, pp. 1745- 1749 ,(2015) , 10.1002/HED.23823
Raluca Dumache, Alexandru Florin Rogobete, Ovidiu Horea Bedreag, Mirela Sarandan, Alina Carmen Cradigati, Marius Papurica, Corina Maria Dumbuleu, Radu Nartita, Dorel Sandesc, None, Use of miRNAs as Biomarkers in Sepsis Analytical Cellular Pathology. ,vol. 2015, pp. 186716- 186716 ,(2015) , 10.1155/2015/186716
Elke Platz, Pardeep S. Jhund, Ross T. Campbell, John J. McMurray, Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review European Journal of Heart Failure. ,vol. 17, pp. 906- 916 ,(2015) , 10.1002/EJHF.321
Michael J. Proctor, Paul G. Horgan, Dinesh Talwar, Colin D. Fletcher, David S. Morrison, Donald C. McMillan, Optimization of the systemic inflammation‐based Glasgow Prognostic Score Cancer. ,vol. 119, pp. 2325- 2332 ,(2013) , 10.1002/CNCR.28018